Original paperA randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast
References (13)
- et al.
Failure of chemotherapy to prolong survival in a group of patients with metastatic carcinoma of the breast
Lancet
(1980) - et al.
Comparison of short-term and continuous chemotherapy for advanced breast cancer
Lancet
(1990) - et al.
Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months
EurJ Cancer
(1993) Combination chemotherapy for metastatic breast cancer
Cancer
(1976)Breast cancer and liver metastases—incidence, diagnosis and outcome
J R Soc Med
(1992)Chemotherapeutic approaches in the treatment of breast cancer
Semin Oncol
(1995)
Cited by (52)
The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice
2020, Critical Reviews in Oncology/HematologyCitation Excerpt :Other studies either did not specify how PFS was defined [71–74], or evaluated the period from randomization until progression of disease including a possible reintroduction of chemotherapy in the ‘short’ treatment arm [75]. Overall, 10 out of 13 individual trials indicated a relevant and significant improvement in PFS with longer durations of chemotherapy [64–68,70,71,73,74,76]. Muss et al evaluated both definitions of PFS and found results were only statistically significantly better for the long arm when looking at the first occurrence of disease progression, not including PFS duration of re-introduction of chemotherapy in the ‘short’ treatment arm [76].
Prolonged clinical benefit from the maintenance hormone therapy inpatients with metastatic breast cancer
2013, BreastCitation Excerpt :Even though current practice guideline is to continue the first-line chemotherapy until disease progression [1], the optimal duration of cytotoxic chemotherapy for MBC is still controversial. There have been several trials to investigate the efficacy of maintenance chemotherapy in MBC [2–11]. These trials showed consistent benefit of maintenance therapy in terms of PFS, but improvement of overall survival (OS) was not observed in most of the trials [5].
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab
2012, BreastCitation Excerpt :Metastatic breast cancer is considered a chronic disease, where the aim of treatment is the improvement of quality of life and prolongation of survival. Developments in therapeutic interventions for metastatic breast cancer have led to improvements in time to disease progression, time to treatment failure, quality of life, and overall survival.1–5 Research is now focused on developing novel treatment strategies that might be as effective but less toxic than standard chemotherapy.
Anthracyclines in the management of metastatic breast cancer: State of the art
2011, European Journal of Cancer, Supplement